New randomized controlled trial shows that addition of Smith+Nephew's REGENETEN™ Bioinductive Implant delivers 86% reduction in rotator cuff re-tear rates at 12 months
/PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE: SNN), the global medical technology company, today announces promising new data furthering a number of published...
United States United Kingdom City Of Universitario Ramony Cajal Martin Hernandezc Bioinductive Acta Biomed
Source: prnewswire.com